BACKGROUND: Pivotal and post-marketing studies demonstrated the impressive efficacy and the good tolerability profile of natalizumab in Multiple Sclerosis patients. On the other hand long-term safety of natalizumab therapy is burdened by the risk of progressive multifocal leukoencephalopathy, especially in anti-JCV seropositive patients treated for more than two years. Some of these patients must stop the drug at the risk of disease reactivation. OBJECTIVES: To evaluate the effects of natalizumab discontinuation in a monocentric cohort of multiple sclerosis patients followed for a mean time of 22.4 months. METHODS: One hundred and ten patients, who stopped therapy after at least 12 infusions, were followed with periodic clinical and magnetic resonance imaging evaluations. One hundred patients started either immunomodulant therapy (n=90) or fingolimod (n=10) while 10 remained without any drug. RESULTS: "Disease-activity free" patients were 25% at one year after discontinuation and annualized relapse rate significantly increased from 0.06 to 0.84 (p<0.0001). We found that the risk of reactivation peaked despite alternative treatments between the second and the eighth month after suspension, a so-called "high risk period". During this period the majority of patients showed a return to pre-natalizumab disease activity while 10% of patients presented a "rebound activity". A higher pre-natalizumab disease activity was correlated with an increased risk of reactivation (p=0.004). CONCLUSIONS: Our data suggest that disease reactivation peaked during a "high risk period" between the second and the eighth month since stopping the drug. During this period no alternative treatments seemed to provide an adequate protection from disease reactivation. Though transient, this phase could be potentially dangerous, therefore we need to develop more effective strategies to deal with this challenge.
BACKGROUND: Pivotal and post-marketing studies demonstrated the impressive efficacy and the good tolerability profile of natalizumab in Multiple Sclerosispatients. On the other hand long-term safety of natalizumab therapy is burdened by the risk of progressive multifocal leukoencephalopathy, especially in anti-JCV seropositive patients treated for more than two years. Some of these patients must stop the drug at the risk of disease reactivation. OBJECTIVES: To evaluate the effects of natalizumab discontinuation in a monocentric cohort of multiple sclerosispatients followed for a mean time of 22.4 months. METHODS: One hundred and ten patients, who stopped therapy after at least 12 infusions, were followed with periodic clinical and magnetic resonance imaging evaluations. One hundred patients started either immunomodulant therapy (n=90) or fingolimod (n=10) while 10 remained without any drug. RESULTS: "Disease-activity free" patients were 25% at one year after discontinuation and annualized relapse rate significantly increased from 0.06 to 0.84 (p<0.0001). We found that the risk of reactivation peaked despite alternative treatments between the second and the eighth month after suspension, a so-called "high risk period". During this period the majority of patients showed a return to pre-natalizumab disease activity while 10% of patients presented a "rebound activity". A higher pre-natalizumab disease activity was correlated with an increased risk of reactivation (p=0.004). CONCLUSIONS: Our data suggest that disease reactivation peaked during a "high risk period" between the second and the eighth month since stopping the drug. During this period no alternative treatments seemed to provide an adequate protection from disease reactivation. Though transient, this phase could be potentially dangerous, therefore we need to develop more effective strategies to deal with this challenge.
Authors: F Esposito; L Ferrè; F Clarelli; M A Rocca; G Sferruzza; L Storelli; M Radaelli; F Sangalli; L Moiola; B Colombo; F Martinelli Boneschi; G Comi; M Filippi; V Martinelli Journal: J Neurol Date: 2018-02-12 Impact factor: 4.849
Authors: Simona Malucchi; Marco Capobianco; Marianna Lo Re; Maria Malentacchi; Alessia di Sapio; Manuela Matta; Francesca Sperli; Antonio Bertolotto Journal: Neurol Ther Date: 2016-12-03
Authors: S K Vainio; A M Dickens; J Tuisku; O Eskola; O Solin; E Löyttyniemi; D C Anthony; J O Rinne; L Airas; M Haaparanta-Solin Journal: EJNMMI Res Date: 2019-05-09 Impact factor: 3.138
Authors: Marianna Lo Re; Marco Capobianco; Paolo Ragonese; Sabrina Realmuto; Simona Malucchi; Paola Berchialla; Giuseppe Salemi; Antonio Bertolotto Journal: Neurol Ther Date: 2015-12-08